Usted está aquí: Inicio->Investigación->->Personal académico
flash departamento

Datos personales
Nombre: Fournier ,  Pierrick Gerard Jean
Categoría: INVESTIGADOR TITULAR
SNI: INVESTIGADOR I
Departamento: Innovación Biomédica
División: Biología Experimental y Aplicada
Correo: fournier@cicese.mx
Extensión: 00000
Página personal: http://usuario.cicese.mx/~fournier
Proyectos
Líneas de investigación
Laboratorios

Publicaciones
2022
  • Calvert, R. D., Fleet, J. C., Fournier, P. G. J., Juárez Camacho, P., Burcham, G. N., Haverkamp, J. M., Guise, T., Ratliff, T. L., & Elzey, B. D. (2022). Monocytic Myeloid-Derived Suppressor Cells from Tumor Tissue Are a Differentiated Cell with Limited Fate Plasticity. ImmunoHorizons, 6(12), 790-806. doi: 10.4049/immunohorizons.2200079. (ID: 28251)
  • Arellano Rodríguez, D. L., Juárez Camacho, P., Verdugo Meza, A. A., Almeida Luna, P. S., Corral Avila, J. A., Drescher, F. C. L., Olvera Rodriguez, F., Jiménez Flores, S. M., Elzey, B. D., Guise, T., & Fournier, P. G. J. (2022). Bone microenvironment-suppressed T cells increase osteoclast formation and osteolytic bone metastases in mice. JOURNAL OF BONE AND MINERAL RESEARCH, 37(8), 1446-1463. doi: 10.1002/jbmr.4615. (ID: 27790)
  • Juárez Camacho, P., Iduarte Frias, B. I., & Fournier, P. G. J. (2022). Transforming growth factor-ß and its signaling pathway in skeletal complications of malignancy. In Dominique Heymann (Eds.), Bone Sarcomas and Bone Metastases - From Bench to Bedside (3 ed., pp. 253-273). Academic Press. (ID: 27718)
2020
  • Fournier, P. G. J., Fajardo Yamamoto, L. M., & Juárez Camacho, P. (2020). TGF-ß and BMP Signaling Pathways in Cancer and Bone: In Sickness and in Health. In Mone Zaidi (Eds.), Encyclopedia of Bone Biology (pp. 281-293). Academic Press. (ID: 26081)
  • Núñez Rivera, A., Fournier, P. G. J., Arellano Rodríguez, D. L., rodriguez hernández, a. g., Vazquez Duhalt, R., & Cadena Nava, R. D. (2020). Brome mosaic virus-like particles as siRNA nanocarriers for biomedical purposes. Beilstein Journal of Nanotechnology, 11, 372-382. doi: 10.3762/bjnano.11.28. (ID: 25972)
2019
  • Vazquez Muñoz, R., Meza Villezcas, A., Fournier, P. G. J., Soria Castro, E., Juárez Moreno, K., Gallego Hernández, A., Bogdanchikova, N., Vázquez Duhalt, R., & Huerta Saquero, A. (2019). Enhancement of antibiotics antimicrobial activity due to the silver nanoparticles impact on the cell membrane. PLoS ONE, 14(11), e0224904. doi: 10.1371/journal.pone.0224904. (ID: 25181)
2018
  • Millán Gómez, D. V., Dueñas Espinoza, S., Muñoz, P. L. A., Camacho Villegas, T. A., Elosua, C., Cabanillas Bernal, O., Escalante, T., Almudena, P., Abia, D., Drescher, F. C. L., Fournier, P. G. J., Ramos Ibarra, M. A., Mares, R. E., Paniagua Solís, J. F., Mata González, M. T., Gonzalez Canudas, J., Hoffman, R., Licea Navarro, A. F., & Sánchez Campos, L. N. (2018). In silico-designed mutations increase variable new-antigen receptor single-domain antibodies for VEGF165 neutralization. Oncotarget, 9(46), 28016-28029. doi: 10.18632/oncotarget.25549. (ID: 23951)
  • Sengar, P., Juárez Camacho, P., Verdugo Meza, A. A., Arellano Rodríguez, D. L., Jain, A., Chauhan, K., Hirata Flores, G. A., & Fournier, P. G. J. (2018). Development of a functionalized UV-emitting nanocomposite for the treatment of cancer using indirect photodynamic therapy. JOURNAL OF NANOBIOTECHNOLOGY, 16, 19. doi: 10.1186/s12951-018-0344-3. (ID: 23609)
2017
  • Juárez Camacho, P., Fournier, P. G. J., Mohammad, K., McKenna, R., Davis, H., Peng, X., Niewolna, M., Mauviel, A., Chirgwin, J., & Guise, T. (2017). Halofuginone inhibits TGF-ß/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis. Oncotarget, 8(49), 86447-86462. doi: 10.18632/oncotarget.21200. (ID: 22561)
  • Trivedi, T., Zheng, Y., Fournier, P. G. J., Murthy, S., John, S., Schillo, S., Dunstan, C. R., Mohammad, K., Zhou, H., Seibel, M. J., & Guise, T. (2017). The vitamin D receptor is involved in the regulation of human breast cancer cell growth via a ligand-independent function in cytoplasm. Oncotarget, 8(16), 26687-26701. doi: 10.18632/oncotarget.15803. (ID: 22456)
2015
  • Suvannasankha, A., Tompkins, D., Edwards, D., Petyaykina, K., Crean, C., Fournier, P. G. J., Parker, J., Sandusky, G., Ichikawa, S., Imel, E., & Chirgwin, J. (2015). FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells. Oncotarget, 6(23), 19647-19660. doi: 10.18632/oncotarget.3794. (ID: 19183) (E)
  • Stayrook, K., Mack, J., Cerabona, D., Edwards, D., Bui, H., Niewolna, M., Fournier, P. G. J., Mohammad, K., Waning, D., & Guise, T. (2015). TGFß-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis. BoneKEy Reports, 4(719), 13. doi: 10.1038/bonekey.2015.88. (ID: 19419) (E)
  • Fournier, P. G. J., Juárez Camacho, P., Jiang, G., Clines, G., Niewolna, M., Kim, H. S., Walton, H., Peng, X., Liu, Y., Mohammad, K., Wells, C., Chirgwin, J., & Guise, T. (2015). The TGF-ß Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone. CANCER CELL, 27(6), 809-821. doi: 10.1016/j.ccell.2015.04.009. (ID: 19179) (E)
2014
  • Fournier, P. G. J., Juárez Camacho, P., & Guise, T. (2014). Tumor-bone interactions: there is no place like bone. In Dominique Heymann (Eds.), Bone Cancer - Primary Bone Cancers and Bone Metastases (2 ed.). Academic Press. (ID: 18148) (E)
2012
  • Juárez Camacho, P., Mohammad, K., Yin, J. J., Fournier, P. G. J., McKenna, R., Davis, H., Peng, X., Niewolna, M., Javelaud, D., Chirgwin, J., Mauviel, A., & Guise, T. (2012). Halofuginone Inhibits the Establishment and Progression of Melanoma Bone Metastases. CANCER RESEARCH, 72(23), 6247-6256. doi: 10.1158/0008-5472.CAN-12-1444. (ID: 17656) (E)
2011
  • Stresing, V., Fournier, P. G. J., Bellahcène, A., Benzaïd, I., Mönkkönen, H., Colombel, M., Ebetino, F. H., Castronovo, V., & Clézardin, P. (2011). Nitrogen-Containing Bisphosphonates Can Inhibit Angiogenesis In Vivo Without the Involvement of Farnesyl Pyrophosphate Synthase. BONE, 48(2), 259-266. doi: 10.1016/j.bone.2010.09.035. (ID: 17659) (E)
  • Mohammad, K., Javelaud, D., Fournier, P. G. J., Niewolna, M., McKenna, R., Peng, X., Duong, V., Dunn, L., Mauviel, A., & Guise, T. (2011). TGF-ß-RI Kinase Inhibitor SD-208 Reduces the Development and Progression of Melanoma Bone Metastases. CANCER RESEARCH, 71(1), 175-184. doi: 10.1158/0008-5472.can-10-2651. (ID: 17657) (E)
2010
  • Alexaki, V., Javelaud, D., Van Kempen, L., Mohammad, K., Dennler, S., Luciani, F., Hoek, K., Juárez Camacho, P., Goydos, J., Fournier, P. G. J., Sibon, C., Bertolotto, C., Verrecchia, F., Saule, S., Delmas, V., Ballotti, R., Larue, L., Saiag, P., Guise, T., & Mauviel, A. (2010). GLI2-Mediated Melanoma Invasion and Metastasis. Journal of the National Cancer Institute, 102(15), 1148-1159. doi: 10.1093/jnci/djq257. (ID: 17660) (E)
  • Fournier, P. G. J., Stresing, V., Ebetino, F. H., & Clézardin, P. (2010). How Do Bisphosphonates Inhibit Bone Metastasis In Vivo. NEOPLASIA, 12(7), 571-578. doi: 10.1593/neo.10282. (ID: 17661) (E)
2009
  • Mohammad, K., Fournier, P. G. J., Guise, T., & Chirgwin, J. (2009). Agents Targeting Prostate Cancer Bone Metastasis. Anti-Cancer Agents in Medicinal Chemistry, 9(10), 1079-1088. doi: 10.2174/187152009789735008. (ID: 17663) (E)
  • Dunn, L., Mohammad, K., Fournier, P. G. J., McKenna, R., Davis, H., Niewolna, M., Peng, X., Chirgwin, J., & Guise, T. (2009). Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS ONE, 4(9), e6896. doi: 10.1371/journal.pone.0006896. (ID: 17664) (E)
  • Fournier, P. G. J., Dunn, L., Clines, G., & Guise, T. (2009). Tumor-Bone Cell Interactions in Bone Metastases. In Dominique Heymann (Eds.), Bone Cancer - Progression and Therapeutic Approaches (1 ed., pp. 11-40). Academic Press. (ID: 18147) (E)
2008
  • Fournier, P. G. J., Daubiné, F., Lundy, M., Rogers, M., Ebetino, F. H., & Clézardin, P. (2008). Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. CANCER RESEARCH, 68(21), 8945-8953. doi: 10.1158/0008-5472.CAN-08-2195. (ID: 17665) (E)
2007
  • Javelaud, D., Mohammad, K., McKenna, R., Fournier, P. G. J., Luciani, F., Niewolna, M., André, J., Delmas, V., Larue, L., Guise, T., & Mauviel, A. (2007). Stable Overexpression of Smad7 in Human Melanoma Cells Impairs Bone Metastasis. CANCER RESEARCH, 67(5), 2317-2324. doi: 10.1158/0008-5472.CAN-06-3950. (ID: 17668) (E)
2006
2005
  • Clézardin, P., Ebetino, F. H., & Fournier, P. G. J. (2005). Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. CANCER RESEARCH, 65(12), 4971-4974. doi: 10.1158/0008-5472.CAN-05-0264. (ID: 17671) (E)
  • Colombel, M., Filleul, S., Fournier, P. G. J., Merle, C., Guglielmi, J., Courtin, A., Degeorges, A., Serre, C. M., Bouvier, R., Clézardin, P., & Cabon, F. (2005). Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. CANCER RESEARCH, 65(1), 300-308. (ID: 17673) (E)
2003
  • Peyruchaud, O., Serre, C. M., NicAmhlaoibh, R., Fournier, P. G. J., & Clézardin, P. (2003). Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity. Journal of Biological Chemistry, 278(46), 45826-45832. doi: 10.1074/jbc.M309024200. (ID: 17675) (E)
  • Clézardin, P., Fournier, P. G. J., Boissier, S., & Peyruchaud, O. (2003). In vitro and in vivo antitumor effects of bisphosphonates. CURRENT MEDICINAL CHEMISTRY, 10(2), 173-180. doi: 10.2174/0929867033368529. (ID: 17674) (E)
2002
  • Fournier, P. G. J., Boissier, S., Filleur, S., Guglielmi, J., Cabon, F., Colombel, M., & Clézardin, P. (2002). Bisphosphonates Inhibit Angiogenesis in Vitro and Testosterone-stimulated Vascular Regrowth in the Ventral Prostate in Castrated Rats. CANCER RESEARCH, 62(22), 6538-6544. (ID: 17676) (E)

Carretera Ensenada-Tijuana No. 3918, Zona Playitas, C.P. 22860, Ensenada, B.C. Mexico. Teléfono: 01(646)175-05-00

w3cCSS w3cXML

CICESE, MÉXICO - ALGUNOS DERECHOS RESERVADOS © 2011 - POLÍTICAS DE PRIVACIDAD